{"symbol":"BMY","fiscalQuarter":"Q3-2021","reportDate":"2021-10-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2021","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 3.0%","keyNumbers":[{"metric":"EPS","actual":"$2.00","expected":"N/A","surprise":"+4.82%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strength of their pipeline despite not providing specific guidance.","They acknowledged ongoing challenges in the market but expressed confidence in future growth."],"summary":"Overall, management conveyed a sense of cautious optimism about their product pipeline and future prospects. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 3.0%. This decline may reflect investor concerns about the lack of revenue details and future guidance, which could lead to uncertainty in the stock's performance moving forward.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2021 earnings: EPS beat by 4.82%. Stock down 3.0%. Full breakdown."}}